Showing results (411-420 of 560) with videos related to
Sort By:
Pageof 56
Intestinal Research|May 9, 2024
Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studiesTaku Kobayashi, Katsuyoshi Matsuoka, Mamoru Watanabe, et al.Journal of Gastroenterology|September 22, 2006
Negative regulation of intracellular hepatitis C virus replication by interferon regulatory factor 3Tsuyoshi Yamashiro, Naoya Sakamoto, Masayuki Kurosaki, et al.Gastroenterology|February 28, 2004
Hyperexpression of inducible costimulator and its contribution on lamina propria T cells in inflammatory bowel diseaseToshiro Sato, Takanori Kanai, Mamoru Watanabe, et al.Surgery Today|February 1, 2018
Postoperative therapy with infliximab for Crohn's disease: a 2-year prospective randomized multicenter study in JapanKouhei Fukushima, Akira Sugita, Kitaro Futami, et al.Diabetologia|October 23, 2023
Novel time-resolved reporter mouse reveals spatial and transcriptional heterogeneity during alpha cell differentiationMiwa Himuro, Yuka Wakabayashi, Tomomi Taguchi, et al.Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association|March 11, 2003
Teleconsultation practice guidelines: report from G8 Global Health Applications Subproject 4Michael Nerlich, E Andrew Balas, Thomas Schall, et al.Antimicrobial Agents and Chemotherapy|December 29, 2011
Identification of novel N-(morpholine-4-carbonyloxy) amidine compounds as potent inhibitors against hepatitis C virus replicationAkiko Kusano-Kitazume, Naoya Sakamoto, Yukiko Okuno, et al.Virology|October 24, 2007
Development of plaque assays for hepatitis C virus-JFH1 strain and isolation of mutants with enhanced cytopathogenicity and replication capacityYuko Sekine-Osajima, Naoya Sakamoto, Kako Mishima, et al.Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|January 19, 2007
[Case of severe ulcerative colitis successfully treated with intravenous cyclosporine without high dose corticosteroid]Daisuke Kubota, Takanori Kanai, Fumiro Yui, et al.Digestion|January 17, 2021
Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFα-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 TrialMasakazu Nagahori, Kenji Watanabe, Satoshi Motoya, et al.Pageof 56